P&T COMMITTEE MEETING Agenda
January 9, 2018
1:00 p.m. – 5:00 p.m.

303 E. 17th Ave, 7th Floor Conference Rooms (7ABC), Denver, CO 80203

- Committee Member Introductions: openings/new appointments
- Vote on New Chair/Vice Chair

Unfinished Business and General Orders
- Approval of minutes from October 03, 2017 P&T meeting
- Update on Hepatitis C Virus Treatments
- Update on Anti-Depressants (Newer Generation)
- Update on Anti-Emetics
- Update on Anti-Herpetic Agents (Oral and Topical)
- Update on Anti-Platelets
- Update on Epinephrine Products
- Update on NSAIDs (Oral and Non-Oral)
- Update on Proton Pump Inhibitors
- Update on Pulmonary Arterial Hypertension (PAH) Agents
  - Endothelial Antagonists
  - Phosphodiesterase Inhibitors
  - Prostanoids
- Update on Targeted Immune Modulators (TIMs)
- Update on Mass review drug classes:
  - Fluoroquinolones (Oral)
  - Pancreatic Enzymes
  - H. Pylori Treatments
  - Pulmonary Arterial Hypertension Agents: Guanylate Cyclase Stimulators
  - Triptans

New Business

1. Review Sunshine Law

2. P&T Policy and Procedure update

3. Updates from the Prior Authorization Call Center
Drug Classes Up for Review:
- Review of Atypical Antipsychotics (Oral)
- Review of Growth Hormones
- Review of Insulins
- Review of Intranasal Corticosteroids
- Review of Multiple Sclerosis Agents
- Review of Neurocognitive Disorder Agents
- Review of Ophthalmic Allergy Agents
- Review of Sedative Hypnotics
  - Non-Benzodiazepine
  - Benzodiazepine
- Review of Statins (single ingredient)
- Mass review drug classes*:
  - Leukotriene Modifiers
  - Statin Combinations

Each Review will contain:
- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

*Mass review drug classes will only include:
- Overview for each Drug Class, including market share and FDA updates

Upcoming Meeting Date: Tuesday, April 10, 2018; 1:00 p.m. – 5:00 p.m.

Presentations:

Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email at brittany.schock@state.co.us to give advance notice to present at the meeting. Written public comments can be submitted to Jessica Czechowski, Clinical Account Manager jlczechowski@magellanhealth.com (carbon copy Brittany Schock) and will be distributed to all P&T Committee Members. Please provide public comments by January 5th, 2018 for dissemination to the P&T Committee.